Key statistics
On Monday, Oric Pharmaceuticals Inc (4TZ:BER) closed at 8.65, 71.29% above the 52 week low of 5.05 set on Oct 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.75 |
---|---|
High | 8.75 |
Low | 8.60 |
Bid | 8.50 |
Offer | 9.35 |
Previous close | 8.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 70.54m |
Free float | 64.10m |
P/E (TTM) | -- |
Market cap | 677.91m USD |
EPS (TTM) | -1.76 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 20:40 BST.
More ▼
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
- ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
- ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
- ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
- ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
- ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
More ▼